High rate of non-adherence to insulin pump: over prescription, overuse or misuse? A population-based case-cohort study.
|
|
- Asher Watson
- 5 years ago
- Views:
Transcription
1 High rate of non-adherence to insulin pump: over prescription, overuse or misuse? A population-based case-cohort study. Dr. Eugene Merzon MD; Ilia Merhasin, MBA; Dr. Avivit Golan-Cohen MD ; Dr. Shmuel Levit, MD, PhD; Prof. Shlomo Vinker, MD, MHA. Department of Managed Care, Medical Division, Leumit Health Services, Department of Family Medicine Tel Aviv University
2 Background
3 Background Dean Kamen, Inventor, Innovator & Entrepreneur
4 Background
5 Background Insulin pump Tubing Cannula Fixator Reservoir
6 Insulin Pumps on the Market Accu-Chek Combo System Asante Snap Insulin Pump System MiniMed Paradigm Real-Time Revel System (523/723) MiniMed 530G with Enlite (551/751) OmniPod Insulin Management System OneTouch Ping t:slim Insulin Pump V-Go Disposable Insulin Delivery Device Roche Health Solutions Asante Solutions Medtronic MiniMed Medtronic MiniMed Insulet Corporation Animas Tandem Diabetes Care Valeritas, Inc.
7 Background Clinical effectiveness of insulin pumps in Type 1 Diabetes A 2010 Cochrane review compared the use of CSII vs. MDI insulin regimens (23 randomized studies involving 976 patients with T1DM): A significant difference was documented in HbA 1c response, favoring IP. IP users demonstrated greater improvements in quality of life measures. Severe hypoglycemia appeared to be reduced in IP users. Misso ML, et al. Cochrane Database Syst Rev. 2010;(1):CD doi(1):cd CSII: continuous subcutaneous insulin infusion MDI: multiple daily injection T1DM: type 1 diabetes mellitus
8 Background Clinical effectiveness of of insulin pumps in Type 2 Diabetes Fewer clinical investigations have examined IP in patients with T2DM In an analysis of four randomized controlled trials involving patients with T2DM: No significant HbA 1c improvements, small differences in hypoglycemic risk, small weight differences were observed with IP vs. MDI over 12 to 52 weeks CSII: continuous subcutaneous insulin infusion T2DM: type 2 diabetes mellitus MDI: multiple daily injection Bode BW. Diabetes Technol Ther. 2010;12 Suppl 1:S17-21.
9 Background There are an increasing numbers of diabetic patients, who have been placed on insulin pump therapy in recent years in Israel. This device is expensive, the mean cost is 2000 GBP for the pump & 1000 GBP annual cost for supplies (NICE 2008). In Israel, patients, who meet the ministry of health criteria, receive the pump and related equipment free of charge. According to industry sponsored clinical trials adherence to insulin pumps is very high(90%), BUT there is uncertainty about patients' adherence to pumps in a real life.
10
11 Background
12 Aim To evaluate adherence to insulin pump and the efficacy of treatment in a real life among type 1 and type 2 adult diabetics. To evaluate clinical, demographic and socioeconomic factors which are associated with failure to adhere to insulin pump therapy among type 1 and type 2 adult diabetics.
13 Methods We conducted a case-cohort study in Leumit Health Services. All patients above 20 years old, with type 1 or type 2 diabetes, who received insulin pump in years, were identified (N=707).
14 Methods Patients who didn't purchased pump maintenance supplies for more than 180 days, were defined as non-adhered or cases (N=355). Cases were compared to the other cohort members, who purchased the supplies and were defined as adhered (N=352).
15 Case-Cohort study design Multivariate regression analysis to calculate Odds ratios for association between patients characteristics and nonadherence to insulin pump treatment Cases Cohort
16 Results
17 Results
18 Results
19 Results
20 Results
21 Results
22 Hypnotic Tx. Results
23 Results P NS P< (9.0; 9.4) P<0.001 P<0.001 P=0.06 P<0.05 P<0.05
24 Results P NS P< (9.0; 9.4) P<0.001 P<0.001 P=0.06 P<0.05 P<0.05
25 Results OR (95%CI) P DM duration longer than 5 years ( ) P<0.001 Non-adherence to diet therapy 4.79 ( ) P<0.001 Uncontrolled DM before IP Tx (HgbA1c 9) 3.94 ( ) P<0.001 Type 2 DM 3.09 ( ) P<0.001 Muslim Arab Ethnicity 2.75 ( ) P<0.001 Age ( ( P<0.001 Smoking 1.65 (CI ) P<0.001 Hypnotic Tx (CI ) P<0.001 Obesity 1.41 ( ). P<0.05 High SES 0.65 ( ) P<0.001
26 Conclusions Only 50% of patients who received insulin pump remained adherent to treatment. Patients who were non- adherent, before starting insulin pump had the greatest odds to quit the pump therapy. Patient who were adherent to insulin pump had better diabetes control, lower rate of hospitalizations & ER visits. Although, patients, who were adherent to insulin pump, had significantly better glycemic control, the mean difference in Hgb A1C in the beginning and in the end of the study was the same in adherent & non-adherent patients.
27 Recommendations According to our data there is an overuse of insulin pump therapy, especially among type 2 DM diabetics. To prevent misuse, we recommend to exclude insulin pump therapy as a criteria for degrees of disability. Insulin pump does not improve adherence to treatment. Recommendation for placing on insulin pump should be based on patients individual characteristics, like history of adherence, health literacy and executive functioning, and not only on Hgb A1C level. IP should be used among highly motivated & educated patients.
28 Recommendations Innovation based on motivation and education. Dean Kamen, Insulin pump inventor, Innovator & Entrepreneur
29 THANK YOU FOR YOUR ATTENTION!
Advances in Diabetes Care Technologies
1979 Advances in Diabetes Care Technologies 2015 Introduction Roughly 20% - 30% of patients with T1DM and fewer than 1% of insulin-treated patients with T2DM use an insulin pump In 2007, the US FDA estimated
More informationAdvances in Diabetes Care Technologies
1979 Advances in Diabetes Care Technologies 2015 Introduction Insulin pump use: ~ 20% - 30% of patients with T1DM < 1% of insulin-treated patients with T2DM 2007 FDA estimates ~375,000 insulin pumps for
More informationPerformance-powered. The OneTouch. Ping insulin pump and meter-remote.
Performance-powered. The OneTouch Ping insulin pump and meter-remote. I We don t just deliver insulin. We deliver outstanding clinical performance. P36337_OTP_DetAid_OmniPodUpdate_r12.indd 1 OneTouch Ping.
More informationBasics of Continuous Subcutaneous Insulin Infusion Therapy. Lubna Mirza, MD Norman Endocrinology Associates 2018
Basics of Continuous Subcutaneous Insulin Infusion Therapy Lubna Mirza, MD Norman Endocrinology Associates 2018 Preamble Roughly 20% - 30% of patients with T1DM and fewer than 1% of insulin-treated patients
More informationAdvances in Diabetes Care Technologies
Advances in Diabetes Care Technologies 1979 2015 Introduction Roughly 20% to 30% of patients with T1DM and fewer than 1% of insulin-treated patients with T2DM use an insulin pump In 2007, the U.S. FDA
More information06/13/17. A. Completed a comprehensive diabetes education program within the past two years; and
Reference #: MC/L011 Page 1 of 4 PRODUCT APPLICATION: PreferredOne Community Health Plan (PCHP) PreferredOne Administrative Services, Inc. (PAS) ERISA PreferredOne Administrative Services, Inc. (PAS) Non-ERISA
More informationInsulin Prior Authorization Criteria For Individuals who Purchased BlueCare / KS Solutions products
Insulin Prior Authorization Criteria For Individuals who Purchased BlueCare / KS Solutions products FDA LABELED INDICATIONS 1-13,16-20 Rapid-Acting Indication Onset Peak Duration Insulins Fiasp (insulin
More informationInsulin Prior Authorization Criteria For Individuals Who Purchased BlueCare/KS Solutions/EPO Products
Insulin Prior Authorization Criteria For Individuals Who Purchased BlueCare/KS Solutions/EPO Products FDA LABELED INDICATIONS 1-13,16-21 Rapid-Acting Indication Onset Peak Duration Insulins Admelog (insulin
More informationDesigned with your patients lives in mind
The Accu-Chek Insight diabetes therapy system Designed with your patients lives in mind With pre-filled insulin cartridge Designed for easy patient training The Accu-Chek Insight diabetes therapy system
More informationType 1 DM. CME Away India & Sri Lanka March 23 - April 7, 2018
Type 1 DM CME Away India & Sri Lanka March 23 - April 7, 2018 Richard A. Bebb MD, ABIM, FRCPC Consultant Endocrinologist Medical Subspecialty Institute Cleveland Clinic Abu Dhabi Copyright 2017 by Sea
More informationDiabetes and Technology. Saturday, September 9, 2017 Aimee G sell, APRN, ANP-C, CDE
Diabetes and Technology Saturday, September 9, 2017 Aimee G sell, APRN, ANP-C, CDE Disclosure Speaker s Bureau: Janssan Pharmaceuticals Current Technology V-Go by Valeritas Continuous Sensors (personal
More informationMEDICAL POLICY Continuous Glucose Monitoring Systems and Insulin Pumps
POLICY: PG0177 ORIGINAL EFFECTIVE: 12/01/08 LAST REVIEW: 02/13/18 MEDICAL POLICY Continuous Glucose Monitoring Systems and Insulin Pumps GUIDELINES This policy does not certify benefits or authorization
More informationMichael L. Levitz Chief Financial Officer. November 15, 2017 Investor Presentation
Michael L. Levitz Chief Financial Officer November 15, 2017 Investor Presentation Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's expectations, anticipations,
More informationUpdates in Diabetes Technology
Updates in Diabetes Technology Jessica Kirk, MSN, RN, CPN, CDE Nurse Manager, Endo ECHO No disclosures Disclosures 1 Objectives Distinguish patients appropriate for continuous glucose monitoring and insulin
More informationInsulin Pump and CGM Usage in the United States and Germany: Results of a Real-World Survey With 985 Subjects
588945DSTXXX10.1177/1932296815588945Journal of Diabetes Science and TechnologyWalsh et al research-article2015 Original Article Insulin Pump and CGM Usage in the United States and Germany: Results of a
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Continuous subcutaneous insulin infusion for the treatment of diabetes (review) Final scope Appraisal objective To review
More informationApproved by: Integrated Health Quality Management Subcommittee Effective Date: Department of Origin: Integrated Healthcare Services.
Reference #: MC/L008 Page: 1 of 8 PRODUCT APPLICATION: PreferredOne Community Health Plan (PCHP) PreferredOne Administrative Services, Inc. (PAS) ERISA PreferredOne Administrative Services, Inc. (PAS)
More informationASHLEY AUSTIN HEATHER MICHAELA RYAN. YOU CAN make managing diabetes easier.
ASHLEY AUSTIN HEATHER MICHAELA RYAN YOU CAN make managing diabetes easier. Overview Insulet s vision and key milestones Why the OmniPod makes CSII adherence easier while improving control The OmniPod Insulin
More informationThe Growing Future of Diabetes: Insulin Pump Therapy in Type 1 and 2 Diabetes
The Growing Future of Diabetes: Insulin Pump Therapy in Type 1 and 2 Diabetes Sarah Dombrowski, PharmD, BCACP Pennsylvania Pharmacists Association 10/20/18 1 Objectives At the completion of this activity,
More informationMEDICAL POLICY Continuous Glucose Monitoring Systems and Insulin Pumps
POLICY: PG0177 ORIGINAL EFFECTIVE: 12/01/08 LAST REVIEW: 05/24/18 MEDICAL POLICY Continuous Glucose Monitoring Systems and Insulin Pumps GUIDELINES This policy does not certify benefits or authorization
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE)
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE) Review of TA151 Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus This guidance was issued in
More informationInsulin Delivery and Glucose Monitoring Methods for Diabetes Mellitus: Comparative Effectiveness
Insulin Delivery and Glucose Monitoring Methods for Diabetes Mellitus: Comparative Effectiveness Prepared for: Agency for Healthcare Research and Quality (AHRQ) www.ahrq.gov Outline of Material Introduction
More informationThe Diamond Study: Continuous Glucose Monitoring In Patients on Mulitple Daily Insulin Injections
8/5/217 The Diamond Study: Continuous Glucose Monitoring In Patients on Mulitple Daily Insulin Injections Richard M. Bergenstal, MD Executive Director International Diabetes Center at Park Nicollet Minneapolis,
More informationGlobal Insulin Pump Market with Focus on United States: Industry Analysis & Outlook ( )
Industry Research by Koncept Analytics Global Insulin Pump Market with Focus on United States: Industry Analysis & Outlook ----------------------------------------- (2018-2022) January 2019 1 Executive
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE) Consideration of consultation responses on review proposal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE) Consideration of consultation responses on review Review of TA151 Continuous subcutaneous insulin infusion for the treatment
More informationAnimas Vibe System World-class insulin pumping meets world-class CGM*
Animas Vibe System World-class insulin pumping meets world-class CGM* Fully integrated with Dexcom G4 PLATINUM CGM* *Continuous glucose monitoring. My Animas pump has really put me in the driver s seat
More informationMEDICAL POLICY Continuous Glucose Monitoring Systems and Insulin Pumps
POLICY: PG0177 ORIGINAL EFFECTIVE: 12/01/08 LAST REVIEW: 07/10/18 MEDICAL POLICY Continuous Glucose Monitoring Systems and Insulin Pumps GUIDELINES This policy does not certify benefits or authorization
More informationWhat is the role of insulin pumps in the modern day care of patients with Type 1 diabetes?
What is the role of insulin pumps in the modern day care of patients with Type 1 diabetes? Dr. Fiona Wotherspoon Consultant in Diabetes and Endocrinology Dorset County Hospital Fiona.Wotherspoon@dchft.nhs.uk
More informationAdvances in Technology in the Treatment of Diabetes Mellitus 2017 How far have we come-how far are we going? Is there a final frontier?
Advances in Technology in the Treatment of Diabetes Mellitus 2017 How far have we come-how far are we going? Is there a final frontier? Alan B Schorr DO FAAIM FACE www.sugardoc.com abs@sugardoc.com Disclosures
More informationUSE OF INSULIN PUMP FOR THE 1 ST TIME IN A GOVERNMENT HOSPITAL JJ HOSPITAL, MUMBAI
USE OF INSULIN PUMP FOR THE 1 ST TIME IN A GOVERNMENT HOSPITAL JJ HOSPITAL, MUMBAI Dr. Hemant Gupta [Associate Prof. & Unit Head, Dept of Medicine, J.J.Hospital, Mumbai] Dr. Ayaz Ahmed [lecturer] Dr. Parag
More informationPumping Insulin is it for your patients?
Pumping Insulin is it for your patients? YOU CAN make managing diabetes easier. Fred Porcase D.O. Disclosures to Participants Conflicts Of Interest and Financial Relationships Disclosures: No professional
More informationBackground: Patch pumps are a relatively new method of insulin delivery. This study explores the accuracy of patch-pumps by
A Comparative Pulse Accuracy Study of Two Commercially Available Patch Insulin Infusion Pumps Jenna L Bowen and Chris J Allender School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff,
More informationInsulin Pump Therapy for Type 2
9501172-011 Insulin Pump Therapy for Type 2 Objective To show the effectiveness of CSII for insulin-taking type 2 patients Key Points Tight glycemic control decreases risk of diabetes-related complications
More informationDiabetes II Insulin pumps; Continuous glucose monitoring system (CGMS) Ernest Asamoah, MD FACE FACP FRCP (Lond)
Diabetes II Insulin pumps; Continuous glucose monitoring system (CGMS) Ernest Asamoah, MD FACE FACP FRCP (Lond) 9501366-011 20110401 Objectives Understand the need for insulin pumps and CGMS in managing
More informationDIAGNOSIS OF DIABETES NOW WHAT?
DIAGNOSIS OF DIABETES NOW WHAT? DISCUSS GOALS FOR DIABETES CARE IDENTIFY COMMON COMPLIANCE- ADHERENCE ISSUES DESCRIBE TECHNOLOGY TO ASSIST AND / OR IMPROVE DIABETES CARE WHAT DO WE WANT OUR PATIENTS TO
More informationGlobal Insulin Pumps Market
Global Insulin Pumps Market 2016-2020 Global Insulin Pumps Market 2016-2020 BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio
More informationPatrick J. Sullivan, President & CEO March 7, 2016 Raymond James 37 th Annual Institutional Conference
Patrick J. Sullivan, President & CEO March 7, 2016 Raymond James 37 th Annual Institutional Conference Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's
More informationToday s Goals 10/6/2017. New Frontiers in Diabetes Technology. Disclosures
New Frontiers in Diabetes Technology Marie E. McDonnell, MD Director, Brigham and Women's Diabetes Program Division of Endocrinology, Diabetes and Hypertension Brigham and Women s Hospital Today s Goals
More informationPatrick J. Sullivan Chief Executive Officer. January 9, 2018 Investor Presentation
Patrick J. Sullivan Chief Executive Officer January 9, 2018 Investor Presentation Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's expectations, anticipations,
More informationFor patients uncontrolled on multiple daily injections of insulin. A quick-start guide for your practice ALL-DAY CONTROL WITH
For patients uncontrolled on multiple daily injections of insulin A quick-start guide for your practice Dosing guidance 1,* V-Go: 3 options 1 For initiating V-Go in patients switching from MDI The majority
More informationThis is a licensed product of Ken Research and should not be copied
1 TABLE OF CONTENTS 1. The US Diabetes Care Devices Market Introduction 1.1. What is Diabetes and it s Types? 2. The US Diabetes Care Devices Market Size, 2007-2013 3. The US Diabetes Care Devices Market
More informationPumps & Sensors made easy. OPADA ALZOHAILI MD FACE Endocrinology Assistant Professor Wayne State University
Pumps & Sensors made easy OPADA ALZOHAILI MD FACE Endocrinology Assistant Professor Wayne State University DeFronzo RA. Diabetes. 2009;58:773-795. Ominous Octet Relationship of b-cell Dysfunction and Development
More informationAudit support for continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (review of technology appraisal guidance 57)
Audit support for continuous subcutaneous insulin (review of technology appraisal guidance 57) Issue date: 2008 Audit support Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus
More informationDiabetes Management with Continuous Glucose Monitoring & Multiple Daily Injections. Aaron Michels MD
Diabetes Management with Continuous Glucose Monitoring & Multiple Daily Injections Aaron Michels MD Outline SMBG & CGM by age group JDRF CGM Trial Sensor Augmented Insulin Pump Therapy for A1c Reduction
More informationCOPYRIGHTED MATERIAL. Chapter 1 An Introduction to Insulin Pump Therapy WHAT IS INSULIN PUMP THERAPY?
Chapter 1 An Introduction to Insulin Pump Therapy This chapter will provide information on what insulin pump therapy is, and how insulin pumps have developed from the early models introduced in the 1970s
More informationWHEN YOUR PANCREAS IS NOT A HAPPY CAMPER A PRESENTATION ON DIABETES MANAGEMENT IN THE CAMP SETTING AMANDA COSCHI, BSCN, RN, CDE
WHEN YOUR PANCREAS IS NOT A HAPPY CAMPER A PRESENTATION ON DIABETES MANAGEMENT IN THE CAMP SETTING AMANDA COSCHI, BSCN, RN, CDE MAY 5, 2018 OBJECTIVES Strong understanding of diabetes and its management
More informationMEDICAL POLICY SUBJECT: CONTINUOUS GLUCOSE MONITORING SYSTEMS/ EXTERNAL INSULIN PUMP THERAPY FOR DIABETES EFFECTIVE DATE: 08/17/17
MEDICAL POLICY SUBJECT: CONTINUOUS GLUCOSE MONITORING PAGE: 1 OF: 11 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product,
More informationTechnological advances have led to innovative insulin delivery systems for patients with type 1 diabetes mellitus. In particular,
A Retrospective Review of the Clinical Characteristics and Blood Glucose Data from Cellnovo System Users using Data Collected from the Cellnovo Online Platform Olivia Hautier-Suply, Yasmin Friedmann and
More informationObjectives. The Problem. We ve come a LONG way, Innovations in Diabetes Care and Management. Barbara Walz, RN, BSN, CDE April 26, 2018
Objectives Innovations in Diabetes Care and Management Barbara Walz, RN, BSN, CDE April 26, 2018 1. Briefly discuss the history of diabetes management over the past 100 years 2. Describe the impact of
More informationInsulin pumps. Norman Waugh Warwick Medical School.
Insulin pumps Norman Waugh Warwick Medical School norman.waugh@warwick.ac.uk Insulin pumps Small device to support continuous subcutaneous insulin infusion Alternative to multiple daily injections (MDI)
More informationInsulin Pumps Available in Canada
Insulin Pumps Available in Canada A Comparison from WaltzingTheDragon.ca *Accu-Chek Animas Ping/Vibe Medtronic Minimed 630G Omnipod ABOUT FORM: Is the insulin pump Tubing- Free? Is the pump? Or Water-Resistant?
More informationAre Current Insulin Pumps Accessible to Blind and Visually Impaired People?
Journal of Diabetes Science and Technology Volume 3, Issue 3, May 2009 Diabetes Technology Society CLINICAL APPLICATIONS Are Current Insulin Pumps Accessible to Blind and Visually Impaired People? Darren
More informationDR LEELARATHNA LALANTHA (Orcid ID : ) Comparison of different insulin pump makes under
DR LEELARATHNA LALANTHA (Orcid ID : 0000-0001-9602-1962) Article type : Research Article Comparison of different insulin pump makes under routine care conditions in adults with Type 1 diabetes Short title:
More informationCOMPANY OVERVIEW. July 30, 2018
COMPANY OVERVIEW July 30, 2018 SAFE HARBOR & NON-GAAP FINANCIAL MEASURES Forward Looking Statements Certain statements in this presentation constitute forward-looking statements, including, without limitation,
More informationThe Realities of Technology in Type 1 Diabetes
The Realities of Technology in Type 1 Diabetes May 6, 2017 Rosanna Fiallo-scharer, MD Margaret Frederick, RN Disclosures I have no conflicts of interest to disclose I will discuss some unapproved treatments
More information1 Dexcom G4 Platinum User Guide May 2012
1 Dexcom G4 Platinum User Guide May 2012 Page 1. Dexcom G4 PLATINUM Continuous Glucose Monitoring System. CE marked for use in 1Dexcom G4 User Guide, May 2012. LBL-011277 Rev04. color display. Dexcom G4
More informationNational Best Practice Guides: Inpatients on Continuous Subcutaneous Insulin Infusion (CSII)
Gold Sponsors: Silver Sponsors: National Best Practice Guides: Inpatients on Continuous Subcutaneous Insulin Infusion (CSII) #abcdipn17 @uk_ipn Bronze Sponsors: The sponsoring pharmaceutical companies
More informationCOMPANY OVERVIEW. April 26, 2018
COMPANY OVERVIEW April 26, 2018 SAFE HARBOR & NON-GAAP FINANCIAL MEASURES Forward Looking Statements Certain statements in this presentation constitute forward-looking statements, including, without limitation,
More information5/16/2018. Integrating Diabetes Technology Into your Practice : Insulin Pump Therapy. Diosclosures. What exactly is an Insulin Pump?
Integrating Diabetes Technology Into your Practice : Insulin Pump Therapy Lucia M. Novak, MSN, ANP BC, BC ADM, CDTC Director, Riverside Diabetes Center, Riverside Medical Associates Riverdale, MD Adjunct
More informationA pump for every body.
A quick look at Animas Vibe A pump for every body. Even for the most insulin sensitive. Every body needs accuracy. Here s why: For anyone with diabetes, having the right amount of insulin at just the right
More informationPolicy and Procedure DEPARTMENT: Medical Management
PAGE: 1 of 5 SCOPE: Louisiana Healthcare Connections (Plan) and Member Services Departments. PURPOSE: To provide guidelines for the authorization of ambulatory insulin pumps. WORK PROCESS: 1. Purchase
More informationWhen Will CGM Replace SMBG? Roy W. Beck, MD, PhD. JAEB Center for Health Research Tampa, Florida
When Will CGM Replace SMBG? Roy W. Beck, MD, PhD JAEB Center for Health Research Tampa, Florida Financial Disclosures Dr. Beck does not have any personal conflicts of interest His employer, the JAEB Center
More informationOutcomes assessed in the review The outcomes assessed in the review and used as model inputs were the incident rates of:
The cost-effectiveness of continuous subcutaneous insulin infusion compared with multiple daily injections for the management of diabetes Scuffham P, Carr L Record Status This is a critical abstract of
More information10:20 AM March 5, B 100% 235 u. 124 mg/dl 3 HRS INSULIN ON BOARD:
DEXCOM G5 MOBILE CGM COMPATIBLE B 100% 235 u INSULIN ON BOARD: OPTIONS 10:20 AM March 5, 2017 400 350 300 250 200 150 100 50 1.1 u 1:09 hrs BOLUS 124 mg/dl 3 HRS The pump that gets updated, not outdated.
More informationEffective Health Care Program
Comparative Effectiveness Review Number 57 Effective Health Care Program Methods for Insulin Delivery and Glucose Monitoring: Comparative Effectiveness Executive Summary Background Diabetes mellitus is
More informationDiabetes Care Publish Ahead of Print, published online February 25, 2010
Diabetes Care Publish Ahead of Print, published online February 25, 2010 Quality of Life and costs of IP vs. Health related quality of life, treatment satisfaction and costs associated with intraperitoneal
More informationReport Reference Guide
Report Reference Guide How to use this guide Each type of CareLink report and its components are described in the following sections. Report data used to generate the sample reports was from sample patient
More informationInsulin Pumps - Medical Devices Pipeline Assessment, 2016
Report Information More information from: https://www.wiseguyreports.com/reports/467730-insulin-pumps-medical-devices-pipeline-assessment- 2016 Insulin Pumps - Medical Devices Pipeline Assessment, 2016
More informationINTRAVENOUS (IV) THERAPY AND VEIN ACCESS: GLOBAL MARKETS
INTRAVENOUS (IV) THERAPY AND VEIN ACCESS: GLOBAL MARKETS HLC046C November 2014 Mary C. Patton Project Analyst ISBN: 1-56965-982-6 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215
More informationFuture Direction of Artificial Pancreas. Roy W. Beck, MD, PhD. JAEB Center for Health Research Tampa, Florida
Future Direction of Artificial Pancreas Roy W. Beck, MD, PhD JAEB Center for Health Research Tampa, Florida Financial Disclosures Dr. Beck does not have any personal conflicts of interest His employer,
More informationCompany Overview February 26, 2019
Company Overview February 26, 2019 SAFE HARBOR Cautionary Note Regarding Forward-Looking Statements Certain statements in this presentation constitute forward-looking statements, including, without limitation,
More informationInsulin Pumps - External
Insulin Pumps - External Policy Number: Original Effective Date: MM.01.004 04/01/2011 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 04/01/20174/1/2018 Section: DME Place(s) of
More informationDiabetes Technology Continuous Subcutaneous Insulin Infusion Therapy And Continuous Glucose Monitoring In Adults: An Endocrine Society Clinical
Diabetes Technology Continuous Subcutaneous Insulin Infusion Therapy And Continuous Glucose Monitoring In Adults: An Endocrine Society Clinical Practice Guideline Task Force Members Anne Peters, MD (Chair)
More informationDiabetes Technology Update. Sarah Konigsberg, MD Diabetes & Endocrine Assoc. April 7, 2018
Diabetes Technology Update Sarah Konigsberg, MD Diabetes & Endocrine Assoc. April 7, 2018 Disclosures None No future technologies are FDA approved Continuous Glucose Monitors Continuous Glucose Monitors
More informationNEW TECHNOLOGIES FOR MANAGING DIABETES ANGELA THOMPSON DNP, FNP-C, BC-ADM, CDE, FAANP
NEW TECHNOLOGIES FOR MANAGING DIABETES ANGELA THOMPSON DNP, FNP-C, BC-ADM, CDE, FAANP No commercial support or sponsorship was received for this project I have nothing to disclose OBJECTIVES Identify at
More informationInsulin Pump Therapy in children. Prof. Abdulmoein Al-Agha, FRCPCH(UK)
Insulin Pump Therapy in children Prof. Abdulmoein Al-Agha, FRCPCH(UK) aagha@kau.edu.sa Highlights Evolution of insulin pump Pumps mimics Pancreas Goals of diabetes care What lowers HbA1c Criteria for selection
More informationName of Policy: Continuous or Intermittent Monitoring of Glucose in the Interstitial Fluid
Name of Policy: Continuous or Intermittent Monitoring of Glucose in the Interstitial Fluid Policy #: 038 Latest Review Date: December 2016 Category: DME Policy Grade: B Background/Definitions: As a general
More informationPaolo Di Bartolo U.O di Diabetologia Dip. Malattie Digestive & Metaboliche AULS Prov. di Ravenna. Ipoglicemie e Monitoraggio Glicemico
Paolo Di Bartolo U.O di Diabetologia Dip. Malattie Digestive & Metaboliche AULS Prov. di Ravenna Ipoglicemie e Monitoraggio Glicemico Management of Hypoglycaemia.if hypoglycemia is a problem, the principles
More informationFor more comprehensive information, please refer to the t:connect Application User Guide available online at: Getting Started Guide.
Congratulations on the purchase of your new insulin pump from Tandem Diabetes Care. Your decision to use insulin pump therapy is a sign of your commitment to actively manage your diabetes. This guide provides
More informationDIABETES LANDSCAPE Market, Technology and Intellectual Property
DIABETES LANDSCAPE Market, Technology and Intellectual Property A Joint Research Report from Espicom and UBM TechInsights. This report is the result of a collaborative venture between UBM TechInsights
More informationWith new technology available to
Insulin Pump Therapy: Who, Why, and How Alyssa Kanagaki Greenleaf, BA, MHS, PA-C With new technology available to aid patients, diabetes management in the 21st century is moving beyond metformin. Among
More informationMEDICAL POLICY SUBJECT: CONTINUOUS GLUCOSE MONITORING SYSTEMS/ EXTERNAL INSULIN PUMP THERAPY FOR DIABETES EFFECTIVE DATE: 08/17/17, 08/16/18
MEDICAL POLICY SUBJECT: CONTINUOUS GLUCOSE MONITORING PAGE: 1 OF: 12 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product (including
More informationContinuous Glucose Monitoring Devices Pharmacy Policy
Line of Business: All Line of Business Effective date: August 16, 2017 Revision date: August 16, 2017 Continuous Glucose Monitoring Devices Pharmacy Policy This policy has been developed through review
More informationAdherence to therapy. Kamlesh Khunti University of Leicester, UK. William Polonsky University of California San Diego, USA
Adherence to therapy Kamlesh Khunti University of Leicester, UK William Polonsky University of California San Diego, USA 1 Dualities of interest Kamlesh Khunti: Honoraria for speaking, advising or research
More informationThe next five years in diabetes technology: closed-loop systems
The next five years in diabetes technology: closed-loop systems J. H. (Hans) DeVries Academic Medical Center at the University of Amsterd, the Netherlands Keystone, CO, 19 July 2013 Disclosure AP@home,
More informationNational Medical Policy
National Medical Policy Subject: Policy Number: Insulin Infusion Pumps NMP477 Effective Date*: October 2003 Updated: April 2017 This National Medical Policy is subject to the terms in the IMPORTANT NOTICE
More informationStandards of Care in Diabetes What's New? Veronica Brady, FNP-BC, PhD, BC-ADM,CDE Karmella Thomas, RD, LD,CDE
Standards of Care in Diabetes 2016-- What's New? Veronica Brady, FNP-BC, PhD, BC-ADM,CDE Karmella Thomas, RD, LD,CDE Terminology No longer using the term diabetic. Diabetes does not define people. People
More informationPredicts and helps prevent lows with. zero fingersticks NOW FEATURING BASAL-IQ TECHNOLOGY
Predicts and helps prevent lows with * zero fingersticks NOW FEATURING BASAL-IQ TECHNOLOGY Basal-IQ Technology is not a substitute for active self-management of your diabetes. Please see back cover for
More informationCorporate Medical Policy
Corporate Medical Policy Continuous Monitoring of Glucose in the Interstitial Fluid File Name: Origination: Last CAP Review: Next CAP Review: Last Review: continuous_monitoring_of_glucose_in_the_interstitial_fluid
More informationApproach to the Young child & Parent with Child with DM Best Structure for Continued Care
Approach to the Young child & Parent with Child with DM Best Structure for Continued Care M.S. Limbe MD Paediatric Endcocrinologist Aga Khan University Hospital, Nairobi Approach to the Young Child & Parent
More informationControl of Glycemic Variability for Reducing Hypoglycemia Jae Hyeon Kim
Control of Glycemic Variability for Reducing Hypoglycemia Jae Hyeon Kim Division of Endocrinology and Metabolism, Samsung Medical Center, Sungkyunkwan University School of Medicine Conflict of interest
More informationThis certificate-level program is non-sponsored.
Program Name: Diabetes Education : A Comprehensive Review Module 5 Intensive Insulin Therapy Planning Committee: Michael Boivin, B. Pharm. Johanne Fortier, BSc.Sc, BPh.LPh, CDE Carlene Oleksyn, B.S.P.
More informationComparative table of insulin pumps
Comparative table of insulin pumps Pumps reviewed: insight (Roche Veo 640G Mylife OmniPod Mylife S () The first stop for professional medicines advice www.sps.nhs.uk Authored May 2018 Insight OmniPod S
More informationCigna Medical Coverage Policy
Cigna Medical Coverage Policy Subject External Insulin Pumps Table of Contents Coverage Policy... 1 General Background... 3 Coding/Billing Information... 10 References... 11 Effective Date... 4/15/2017
More informationCareLink. software REPORT REFERENCE GUIDE. Management Software for Diabetes
CareLink Management Software for Diabetes software REPORT REFERENCE GUIDE How to use this guide Each type of CareLink report and its components are described in the following sections. Report data used
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC)
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC) June 2017 Review: June 2020 (earlier if required see recommendations) Bulletin 255: Insulin aspart New Formulation - Fiasp JPC Recommendations:
More informationAbstract ORIGINAL ARTICLES. Background: Methods: Results: Conclusions: Journal of Diabetes Science and Technology
Journal of Diabetes Science and Technology Volume 2, Issue 3, May 2008 Diabetes Technology Society ORIGINAL ARTICLES Laboratory-Based Non-Clinical Comparison of Occlusion Rates Using Three Rapid-Acting
More informationGlucometers Gastrostomy Tubes Nasogastric Tubes Insulin pumps Continuous Glucose monitoring system Closed Loop Smart phones/tablets
Devices Glucometers Gastrostomy Tubes Nasogastric Tubes Insulin pumps Continuous Glucose monitoring system Closed Loop Smart phones/tablets Accuracy Glucometers The ISO (International Organization for
More informationValeritas. Cowen Health Care Conference. Corporate Presentation. NASDAQ: VLRX March 12, 2018
Cowen Health Care Conference Valeritas Corporate Presentation NASDAQ: VLRX March 12, 2018 Improving health and simplifying life for people with diabetes NASDAQ: VLRX John Timberlake, CEO Improving health
More informationInsulin Pumps and Glucose Sensors in Diabetes Management
Diabetes Update+ 2014 Congress Whistler, British Columbia Friday March 21, 2014ǀ 8:15 8:45 am Insulin Pumps and Glucose Sensors in Diabetes Management Bruce A Perkins MD MPH Division of Endocrinology Associate
More information